Candriam Luxembourg S.C.A. increased its stake in Neurocrine Biosciences, Inc. (NASDAQ:NBIX) by 86.6% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 461,000 shares of the company’s stock after buying an additional 214,000 shares during the period. Candriam Luxembourg S.C.A. owned about 0.52% of Neurocrine Biosciences worth $21,207,000 as of its most recent SEC filing.
Other large investors also recently added to or reduced their stakes in the company. Vanguard Group Inc. increased its stake in Neurocrine Biosciences by 4.6% in the first quarter. Vanguard Group Inc. now owns 6,735,965 shares of the company’s stock valued at $291,666,000 after buying an additional 293,755 shares during the period. BlackRock Inc. increased its stake in Neurocrine Biosciences by 14,216.0% in the first quarter. BlackRock Inc. now owns 5,031,933 shares of the company’s stock valued at $217,884,000 after buying an additional 4,996,784 shares during the period. Janus Capital Management LLC increased its stake in Neurocrine Biosciences by 85.0% in the first quarter. Janus Capital Management LLC now owns 4,359,384 shares of the company’s stock valued at $188,759,000 after buying an additional 2,002,899 shares during the period. Perceptive Advisors LLC increased its stake in Neurocrine Biosciences by 1.5% in the first quarter. Perceptive Advisors LLC now owns 3,366,530 shares of the company’s stock valued at $145,771,000 after buying an additional 50,007 shares during the period. Finally, BB Biotech AG increased its stake in Neurocrine Biosciences by 1.6% in the first quarter. BB Biotech AG now owns 3,201,552 shares of the company’s stock valued at $138,627,000 after buying an additional 50,000 shares during the period. 96.21% of the stock is currently owned by institutional investors and hedge funds.
Shares of Neurocrine Biosciences, Inc. (NASDAQ NBIX) opened at 48.84 on Friday. The stock has a 50 day moving average price of $46.79 and a 200 day moving average price of $46.23. The stock’s market capitalization is $4.30 billion. Neurocrine Biosciences, Inc. has a one year low of $37.35 and a one year high of $55.38.
Neurocrine Biosciences (NASDAQ:NBIX) last issued its earnings results on Thursday, August 3rd. The company reported ($0.68) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.66) by $0.02. The firm had revenue of $6.34 million during the quarter, compared to analyst estimates of $0.61 million. During the same quarter in the prior year, the company posted ($0.46) EPS. Equities analysts forecast that Neurocrine Biosciences, Inc. will post ($2.48) earnings per share for the current year.
ILLEGAL ACTIVITY WARNING: “Candriam Luxembourg S.C.A. Has $21.21 Million Stake in Neurocrine Biosciences, Inc. (NASDAQ:NBIX)” was first reported by StockNewsTimes and is the property of of StockNewsTimes. If you are accessing this piece of content on another website, it was stolen and reposted in violation of U.S. & international copyright law. The original version of this piece of content can be viewed at https://stocknewstimes.com/2017/08/04/candriam-luxembourg-s-c-a-has-21-21-million-stake-in-neurocrine-biosciences-inc-nasdaqnbix.html.
NBIX has been the subject of several recent analyst reports. Bank of America Corporation initiated coverage on Neurocrine Biosciences in a research note on Friday, May 5th. They issued a “buy” rating and a $70.00 price target for the company. Oppenheimer Holdings, Inc. set a $60.00 price target on Neurocrine Biosciences and gave the stock a “buy” rating in a research note on Saturday, April 8th. BidaskClub upgraded Neurocrine Biosciences from a “sell” rating to a “hold” rating in a research note on Wednesday, June 21st. Jefferies Group LLC boosted their price target on Neurocrine Biosciences from $59.00 to $65.00 and gave the stock a “buy” rating in a research note on Wednesday, April 12th. Finally, Leerink Swann decreased their price target on Neurocrine Biosciences from $68.00 to $66.00 and set an “outperform” rating for the company in a research note on Thursday, May 25th. One analyst has rated the stock with a sell rating, two have given a hold rating and sixteen have issued a buy rating to the company. The stock presently has a consensus rating of “Buy” and a consensus target price of $67.69.
In related news, insider Malcolm Lloyd-Smith sold 9,960 shares of the company’s stock in a transaction that occurred on Friday, May 19th. The stock was sold at an average price of $53.63, for a total value of $534,154.80. Following the transaction, the insider now directly owns 17,997 shares in the company, valued at $965,179.11. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Christopher Flint Obrien sold 8,734 shares of the company’s stock in a transaction that occurred on Thursday, July 27th. The shares were sold at an average price of $50.00, for a total value of $436,700.00. Following the completion of the transaction, the insider now owns 57,707 shares in the company, valued at $2,885,350. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 28,694 shares of company stock worth $1,504,755. Insiders own 4.80% of the company’s stock.
Neurocrine Biosciences Company Profile
Neurocrine Biosciences, Inc is engaged in discovering and developing pharmaceuticals, in diseases with unmet medical needs, through its research and development (R&D) platform, focused on neurological and endocrine based diseases and disorders. Its three lead late-stage clinical programs are elagolix, which is a gonadotropin-releasing hormone (GnRH) antagonist for endometriosis and uterine fibroids; INGREZZA (valbenazine), which is a vesicular monoamine transporter 2 (VMAT2) inhibitor, for the treatment of movement disorders, and opicapone, which is a selective catechol-O-methyltransferase inhibitor that is an adjunct therapy to preparations of levodopa/Dihydroxyphenylalanine (DOPA) decarboxylase inhibitors for adult patients with Parkinson’s disease.
Receive News & Ratings for Neurocrine Biosciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neurocrine Biosciences Inc. and related companies with MarketBeat.com's FREE daily email newsletter.
